BioSpace News Archive

SCYNEXIS, Inc. today reported financial results for the third quarter ended on September 30, 2022.

Axsome Therapeutics, Inc. today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Conference on Tuesday, November 15, 2022 at 10:45 AM Eastern Time.

TransCode Therapeutics, Inc. today reported positive preclinical results with its immunotherapy candidate, TTX-siPDL1, in pancreatic adenocarcinoma. After two weekly treatments with TTX-siPDL1 combined with the standard-of-care chemotherapeutic, gemcitabine, tumor volumes were 25% of those in untreated animals.

LumiraDx Limited today announced operational and financial results for the third quarter ended September 30, 2022.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, provided a corporate update and reported financial results for the three and nine months ended September 30, 2022.

The death of a loved one, financial or food insecurity, or a newly developed disability were some of the strongest predictors of whether a patient hospitalized for COVID-19 would experience symptoms of long COVID a year later, a new study finds.

Travere Therapeutics, Inc. announced that Company management will participate in the following upcoming conferences.

Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2023 operating results on Monday, November 14, 2022, before the open of the U.S. financial markets.

Neuronetics, Inc. announced the granting of inducement awards to ten new non-executive employees.

Erasca, Inc. reported financial results for the fiscal quarter ended September 30, 2022, and provided business updates.